ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Rochester, MN, USA:

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Rochester, Minnesota, United States and 164 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Rochester, Minnesota, United States and 23 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: MBG453

Phase 2

Novartis
Novartis

Rochester, Minnesota, United States and 27 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Rochester, Minnesota, United States and 222 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Rochester, Minnesota, United States and 43 other locations

This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML...

Active, not recruiting
Acute Myeloid Leukemia
Stem Cell Transplantation
Drug: MT-401

Phase 2

Marker Therapeutics

Rochester, Minnesota, United States and 17 other locations

menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Rochester, Minnesota, United States and 51 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia...

Enrolling
Acute Mixed-Phenotype Leukemia
Acute Lymphoblastic Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

Rochester, Minnesota, United States and 22 other locations

in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with veneto...

Enrolling
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Drug: voruciclib and venetoclax
Drug: voruciclib monotherapy

Phase 1

MEI Pharma

Rochester, Minnesota, United States and 11 other locations

(CAR) T cells), in adult patients with relapsed or refractory acute myeloid leukemia (AML), Minimal Residual Dise ...

Enrolling
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Drug: PRGN-3006 T Cells

Phase 1

Precigen

Rochester, Minnesota, United States and 1 other location

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems